clinical trial · NCT06973577
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase3·active not recruiting·n = 315
ADHDAnxietyGeneralized AnxietySocial Anxiety DisorderCentanafadinePlacebo
brief summary
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
started
Mar 26, 2025
primary completion
Apr 22, 2026
completion
Apr 29, 2026
last updated
Apr 7, 2026
official title
A Phase 3b, Randomized, Double-blind, 8-week, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Centanafadine Once Daily Extended-release Capsules for the Treatment of Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol